JP2018533622A - マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤 - Google Patents

マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤 Download PDF

Info

Publication number
JP2018533622A
JP2018533622A JP2018535266A JP2018535266A JP2018533622A JP 2018533622 A JP2018533622 A JP 2018533622A JP 2018535266 A JP2018535266 A JP 2018535266A JP 2018535266 A JP2018535266 A JP 2018535266A JP 2018533622 A JP2018533622 A JP 2018533622A
Authority
JP
Japan
Prior art keywords
meibomian gland
lipid
agent
acid
disulfide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018535266A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533622A5 (enExample
Inventor
アムセレム，シモン
アルスター，ヤイル
フリードマン，ドロン
ラファエリ，オマー
Original Assignee
アズーラ オフサルミックス エルティーディー．
アズーラ オフサルミックス エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アズーラ オフサルミックス エルティーディー．, アズーラ オフサルミックス エルティーディー． filed Critical アズーラ オフサルミックス エルティーディー．
Publication of JP2018533622A publication Critical patent/JP2018533622A/ja
Publication of JP2018533622A5 publication Critical patent/JP2018533622A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018535266A 2015-09-28 2016-09-28 マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤 Pending JP2018533622A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562233941P 2015-09-28 2015-09-28
US201562233906P 2015-09-28 2015-09-28
US62/233,906 2015-09-28
US62/233,941 2015-09-28
PCT/IB2016/001510 WO2017055924A2 (en) 2015-09-28 2016-09-28 Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020206141A Division JP7138694B2 (ja) 2015-09-28 2020-12-11 マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤

Publications (2)

Publication Number Publication Date
JP2018533622A true JP2018533622A (ja) 2018-11-15
JP2018533622A5 JP2018533622A5 (enExample) 2019-09-05

Family

ID=58408743

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018535266A Pending JP2018533622A (ja) 2015-09-28 2016-09-28 マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤
JP2020206141A Active JP7138694B2 (ja) 2015-09-28 2020-12-11 マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020206141A Active JP7138694B2 (ja) 2015-09-28 2020-12-11 マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤

Country Status (9)

Country Link
US (3) US10688122B2 (enExample)
EP (1) EP3313413B1 (enExample)
JP (2) JP2018533622A (enExample)
KR (1) KR20180090251A (enExample)
CN (2) CN113144203B (enExample)
AU (1) AU2016332966A1 (enExample)
CA (1) CA3000088A1 (enExample)
ES (1) ES3007759T3 (enExample)
WO (1) WO2017055924A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023546452A (ja) * 2020-10-21 2023-11-02 アズーラ オフサルミックス エルティーディー． 眼障害を処置するための化合物および方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
WO2017055924A2 (en) 2015-09-28 2017-04-06 M.G. Therapeutics Ltd. Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
WO2017178892A2 (en) 2016-04-14 2017-10-19 M.G. Therapeutics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
CA3057569A1 (en) * 2017-03-29 2018-10-04 Azura Ophthalmics Ltd. Agents for increasing meibomian gland lipid secretion
CN119157876A (zh) 2017-12-15 2024-12-20 塔苏斯制药有限公司 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
WO2020092402A1 (en) * 2018-10-30 2020-05-07 Harrow Health, Inc. Pharmaceutical compositions of tiopronin and methods for preparing thereof
EP3875092B1 (en) * 2018-11-02 2025-11-19 Kyungpook National University Industry-Academic Cooperation Foundation Composition for prevention or treatment of macular degeneration
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
JP7723603B2 (ja) * 2019-04-12 2025-08-14 アズーラ オフサルミックス エルティーディー． コンタクトレンズ不快感を処置するための組成物および方法
CN114980957A (zh) * 2019-11-04 2022-08-30 阿祖拉眼科有限公司 针对眼内或眼周病症的计量剂量
WO2021136968A2 (en) 2020-01-02 2021-07-08 Azura Ophthalmics Ltd. Manufacturing of selenium disulfide compositions
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
US12286451B2 (en) 2020-11-23 2025-04-29 Medtech Products Inc. Borate ester complexes of α-hydroxy carboxylic acids and their conjugate base buffers
US20220160668A1 (en) 2020-11-23 2022-05-26 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
CN112569179B (zh) * 2020-12-25 2022-12-27 上海交通大学医学院附属第九人民医院 一种可注射水凝胶体系及其制备方法
WO2023215244A1 (en) * 2022-05-02 2023-11-09 Georgetown University Use of n-acetylcysteine to treat lipid disorders and related organ dysfunctions

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07233057A (ja) * 1993-11-05 1995-09-05 Kinki Univ 抗白内障医薬組成物
WO2006137426A1 (ja) * 2005-06-22 2006-12-28 Kowa Company, Ltd. 角結膜疾患の予防又は治療剤
JP2010510961A (ja) * 2006-11-30 2010-04-08 株式会社メニコン 眼科用組成物
JP2010520210A (ja) * 2007-02-28 2010-06-10 アーシエックス セラピューティックス， インコーポレイテッド マイボーム腺分泌を正常化するための方法および組成物
US20110104206A1 (en) * 2009-10-30 2011-05-05 Intratus, Inc. Methods and compositions for sustained delivery of drugs
US20140171886A1 (en) * 2012-12-19 2014-06-19 Senju Usa, Inc. Patch for Treatment of Eyelid Disease Containing Clobetasol
JP2014518275A (ja) * 2011-06-29 2014-07-28 インサイト・ビジョン・インコーポレイテッド 再発性マイボーム腺障害の処置方法およびそれによる再発頻度の減少方法
JP2015514722A (ja) * 2012-04-16 2015-05-21 ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド 皮膚および／または粘膜の処置および／またはケアのための組成物ならびに化粧品組成物または医薬組成物におけるその使用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236730A (en) 1962-01-04 1966-02-22 Miles Lab Blepharitis composition comprising antiseptic, quaternary ammonium compound, keratolytic agent and a chelating compound
US5602130A (en) 1987-03-20 1997-02-11 Allergan Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
EP0930072A1 (en) 1998-01-13 1999-07-21 Kartar Dr. Lalvani Vitamin and mineral containing compositions for the treatment of dry eye
US6348508B1 (en) 2000-04-04 2002-02-19 Bausch & Lomb Incorporated Method for treating dry eye
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
CA2463975A1 (en) 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
FR2833268B1 (fr) 2001-12-12 2005-07-08 Fabre Pierre Dermo Cosmetique Nouvelle association contenant un poloxamer et de l'acide chondroitine sulfurique et/ou une glycoproteine et son utilisation
KR100564386B1 (ko) 2002-05-13 2006-03-27 주식회사 마이코플러스 4-하이드록시-5-메톡시-4-[2-메틸-3-(3-메틸-2-부테닐)-2-옥시란닐]-1-옥사스피로[2,5]옥탄-6-온을 함유한 지루치료용 약제학적 조성물
US8420699B1 (en) * 2002-06-19 2013-04-16 Irvine L. Dubow Composition and methods of treatment using deionized and ozonated solution
CN101897662B (zh) 2002-07-23 2013-05-22 诺瓦提斯公司 包含药物、软膏基质和增溶剂/分散剂的眼用软膏剂组合物
EP2272340B1 (en) 2002-08-19 2018-03-14 Ira Sanders Botulinum toxin
US20040171561A1 (en) 2002-09-03 2004-09-02 Popp Karl F. Topical formulations for treatment of rosacea
US7795203B2 (en) 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
US20060188471A1 (en) 2002-10-31 2006-08-24 Podolsky Daniel K Methods of treating epithelial lesions
GB0225795D0 (en) 2002-11-05 2002-12-11 Guillon Michael Wipes
US20070269537A1 (en) 2003-02-10 2007-11-22 Bioderm Research Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
US20050197614A1 (en) 2004-03-04 2005-09-08 Wilson Pritchard Occlusive biomedical devices, punctum plugs, and methods of use thereof
US20050202097A1 (en) 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
US8455016B2 (en) 2004-03-12 2013-06-04 Melbj Holdings, Llc Treatment for meibomian gland dysfunction or obstruction
EP1621191A1 (en) 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
US20090214676A1 (en) 2005-04-30 2009-08-27 Tissuetech, Inc. Method for treating ocular demodex
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US8083787B2 (en) 2005-07-18 2011-12-27 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
WO2007070463A2 (en) * 2005-12-12 2007-06-21 Riolan Technologies, Inc. Compositions, methods and kits for removing debris from an ocular area
WO2007133703A2 (en) 2006-05-10 2007-11-22 Dxterity Diagnostics Detection of nucleic acid targets using chemically reactive oligonucleotide probes
US8568790B2 (en) 2006-05-31 2013-10-29 Medihoney Pty Ltd. Medicinal compositions containing honey
WO2008027069A1 (en) 2006-08-21 2008-03-06 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction employing fluid
US8249695B2 (en) 2006-09-29 2012-08-21 Tearscience, Inc. Meibomian gland imaging
US8090426B2 (en) 2006-10-27 2012-01-03 Felder Robin A Microelectronic biosensor plug
WO2008058034A1 (en) 2006-11-03 2008-05-15 Qlt Inc. Methods of treating dermatological disorders or conditions
US8128968B2 (en) 2007-08-29 2012-03-06 Tissuetech, Inc. Compositions and methods for treating Demodex infestations
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
US20110059925A1 (en) * 2008-03-26 2011-03-10 Eric Donnenfeld Methods for improving lid margin and tear film function and treatment of lid margin disease using tetracycline family antibiotics
JP5552482B2 (ja) 2008-04-30 2014-07-16 キュー エル ティー インク． 複合涙管挿入物および関連する方法
US8716238B2 (en) 2008-07-10 2014-05-06 Allergan, Inc. Cyclosporin derivatives for treating ocular and dermal diseases and conditions
WO2010033800A2 (en) 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Tetracycline stabilizing formulations
DK2424374T3 (en) 2009-05-01 2018-05-07 Advanced Vision Res Inc Detergent compositions and methods for using the same
CN101612161A (zh) 2009-08-07 2009-12-30 魏谠全 一种眼药组合物及其制剂
WO2011068786A2 (en) 2009-12-02 2011-06-09 Bridge Pharma, Inc. Treating xerophthalmia with compounds increasing meibomian gland secretion
US20120093876A1 (en) 2010-10-13 2012-04-19 Aciex, Inc. Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions
CN104758921A (zh) 2010-11-08 2015-07-08 希尔洛有限公司 缓冲的眼用组合物以及使用其的方法
WO2012092375A1 (en) 2010-12-29 2012-07-05 Inspire Pharmaceuticals, Inc. Method for treating dry eye
JP5952302B2 (ja) 2010-12-29 2016-07-13 ニチャミン、ルイス・ディー 眼の治療のための方法及びキット
WO2012092378A1 (en) 2010-12-29 2012-07-05 Inspire Pharmaceuticals, Inc. Method for treating blepharitis
AU2012209184B2 (en) 2011-01-26 2017-06-15 Allergan, Inc. Androgen composition for treating an opthalmic condition
CN103998464A (zh) 2011-05-20 2014-08-20 学校法人庆应义塾 新型金属蛋白质及其制造方法以及含有所述金属蛋白质的角结膜疾病的预防或治疗剂
ITFI20120044A1 (it) 2012-03-01 2013-09-02 Biodue Spa Formulazione ad uso oftalmico comprendente olio di jojoba.
CA2888647A1 (en) * 2012-11-20 2014-05-30 Revive Therapeutics Inc. The use of bucillamine in the treatment of gout
US9987235B2 (en) * 2013-08-01 2018-06-05 Nicholas L. Abbott Methods and compositions for modifying mucous membranes
HUE14755117T2 (hu) 2013-08-14 2018-12-28 Kalvista Pharmaceuticals Ltd Plazma-kallikrein inhibitorok
EP3139903B1 (en) 2014-05-07 2019-07-03 Croma-Pharma Gesellschaft m.b.H. Aqueous ophthalmic solution and method for treating dry eye syndrome
WO2015187997A1 (en) * 2014-06-04 2015-12-10 Tersus Pharmaceuticals, LLC METHODS OF TREATING CHRONIC DRY EYE DISEASE USING C16:1n7 PALMITOLEATE AND DERIVATIVES THEREOF
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
WO2017055924A2 (en) * 2015-09-28 2017-04-06 M.G. Therapeutics Ltd. Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
WO2017178892A2 (en) * 2016-04-14 2017-10-19 M.G. Therapeutics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
CA3020713A1 (en) * 2016-04-19 2017-10-26 Azura Ophthalmics Ltd. Compositions for the treatment of hyperkeratosis disorders

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07233057A (ja) * 1993-11-05 1995-09-05 Kinki Univ 抗白内障医薬組成物
WO2006137426A1 (ja) * 2005-06-22 2006-12-28 Kowa Company, Ltd. 角結膜疾患の予防又は治療剤
JP2010510961A (ja) * 2006-11-30 2010-04-08 株式会社メニコン 眼科用組成物
JP2010520210A (ja) * 2007-02-28 2010-06-10 アーシエックス セラピューティックス， インコーポレイテッド マイボーム腺分泌を正常化するための方法および組成物
US20110104206A1 (en) * 2009-10-30 2011-05-05 Intratus, Inc. Methods and compositions for sustained delivery of drugs
JP2014518275A (ja) * 2011-06-29 2014-07-28 インサイト・ビジョン・インコーポレイテッド 再発性マイボーム腺障害の処置方法およびそれによる再発頻度の減少方法
JP2015514722A (ja) * 2012-04-16 2015-05-21 ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド 皮膚および／または粘膜の処置および／またはケアのための組成物ならびに化粧品組成物または医薬組成物におけるその使用
US20140171886A1 (en) * 2012-12-19 2014-06-19 Senju Usa, Inc. Patch for Treatment of Eyelid Disease Containing Clobetasol

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, vol. 26, no. 4, JPN6020020529, 2010, pages 329 - 333, ISSN: 0004449556 *
日本結晶学会誌, vol. 56, no. 3, JPN6020020530, 2014, pages 186 - 193, ISSN: 0004449557 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023546452A (ja) * 2020-10-21 2023-11-02 アズーラ オフサルミックス エルティーディー． 眼障害を処置するための化合物および方法

Also Published As

Publication number Publication date
US10688122B2 (en) 2020-06-23
KR20180090251A (ko) 2018-08-10
EP3313413A4 (en) 2018-07-11
WO2017055924A2 (en) 2017-04-06
JP2021063083A (ja) 2021-04-22
EP3313413A2 (en) 2018-05-02
AU2016332966A1 (en) 2018-04-26
CN113144203B (zh) 2025-01-28
US20170087179A1 (en) 2017-03-30
JP7138694B2 (ja) 2022-09-16
US20220226367A1 (en) 2022-07-21
CA3000088A1 (en) 2017-04-06
WO2017055924A3 (en) 2017-07-06
CN108472312A (zh) 2018-08-31
CN113144203A (zh) 2021-07-23
US20200179440A1 (en) 2020-06-11
EP3313413B1 (en) 2024-12-04
EP3313413C0 (en) 2024-12-04
ES3007759T3 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
JP7138694B2 (ja) マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤
KR102350869B1 (ko) 마이봄샘 기능부전의 치료를 위한 조성물 및 방법
KR102541236B1 (ko) 마이봄샘 지질 분비 증가를 위한 작용제
AU2024205420B2 (en) Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
JP2024522878A (ja) 視力改善のための組成物および方法
HK1254414A1 (en) Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
JP2019516796A (ja) 皮膚疾患を治療／予防するためのカルボン酸
HK40004310A (en) Compositions for the treatment of hyperkeratosis disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190725

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200828

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210222